Back to top
more

Novozymes (NVZMY)

(Delayed Data from OTC)

$55.66 USD

55.66
8,488

-0.09 (-0.16%)

Updated Apr 24, 2024 03:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 252)

Industry: Chemical - Specialty

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NVZMY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Novozymes AS falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 162 147 153 181 107
Receivables 621 590 597 493 511
Notes Receivable 0 0 0 0 0
Inventories 527 539 476 362 392
Other Current Assets 64 33 18 23 48
Total Current Assets 1,374 1,309 1,245 1,059 1,057
Net Property & Equipment 1,790 1,710 1,620 1,473 1,531
Investments & Advances 30 32 5 5 6
Other Non-Current Assets 6 5 6 6 4
Deferred Charges 256 230 260 205 174
Intangibles 658 665 799 391 289
Deposits & Other Assets 9 13 5 3 3
Total Assets 4,122 3,962 3,940 3,142 3,064
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 235 265 237 169 167
Current Portion Long-Term Debt 448 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 27 46 77 51 65
Other Current Liabilities 326 658 569 397 453
Total Current Liabilities 1,054 986 903 637 710
Mortgages 0 0 0 0 0
Deferred Taxes/Income 285 252 228 184 132
Convertible Debt 0 0 0 0 0
Long-Term Debt 629 512 585 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 37 156 225 539 433
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,039 1,948 1,998 1,420 1,343
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 82 80 90 87 87
Capital Surplus 0 0 0 0 0
Retained Earnings 1,997 1,850 0 1,725 1,620
Other Equity 5 86 1,852 -90 13
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,084 2,015 1,942 1,723 1,721
Total Liabilities & Shareholder's Equity 4,122 3,962 3,940 3,142 3,064
Total Common Equity 2,084 2,015 1,942 1,723 1,721
Shares Outstanding 468.30 227.20 228.20 297.00 297.00
Book Value Per Share 4.45 8.87 8.51 5.80 5.79

Fiscal Year End for Novozymes AS falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 162 172 153 159
Receivables NA 621 622 611 627
Notes Receivable NA 0 0 0 0
Inventories NA 527 566 579 555
Other Current Assets NA 64 18 27 42
Total Current Assets NA 1,374 1,378 1,370 1,382
Net Property & Equipment NA 1,790 1,851 1,802 1,749
Investments & Advances NA 30 31 32 31
Other Non-Current Assets NA 6 5 4 4
Deferred Charges NA 256 222 236 233
Intangibles NA 658 666 667 663
Deposits & Other Assets NA 9 13 13 13
Total Assets NA 4,122 4,167 4,124 4,076
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 235 213 193 209
Current Portion Long-Term Debt NA 448 344 461 461
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 27 75 55 54
Other Current Liabilities NA 326 259 271 283
Total Current Liabilities NA 1,054 909 999 1,025
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 285 263 269 262
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 629 646 668 672
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 138 133 160
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,039 1,993 2,108 2,161
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 82 82 82 81
Capital Surplus NA 0 0 0 0
Retained Earnings NA 1,997 2,017 1,885 1,770
Other Equity NA 5 75 49 64
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 2,084 2,174 2,016 1,915
Total Liabilities & Shareholder's Equity NA 4,122 4,167 4,124 4,076
Total Common Equity 0 2,084 2,174 2,016 1,915
Shares Outstanding 468.30 468.30 227.20 227.20 227.20
Book Value Per Share 0.00 4.45 9.57 8.87 8.43